Therapeutic Area

Monoclonal Antibody

Therapeutic area intelligence for Monoclonal Antibody with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 3

Companies

Alexion Pharmaceuticals, Inc. →

Janssen Biotech →

Pfizer →

Assets

DARZALEX →

FDA →

ravulizumab →

Recent signals(3)

RegulatoryJune 21, 2026

FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement

The FDA has granted priority review status for the supplemental application of Marstacimab (HYMPAVZI) by Pfizer.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for DARZALEX by Janssen Biotech

The FDA has accepted the supplemental application for DARZALEX (daratumumab) from Janssen Biotech.

ClinicalJune 20, 2026

Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients

A clinical trial is evaluating the efficacy of ravulizumab in reducing delayed graft function (DGF) in kidney transplant patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.